Medrad debuts extravasation detector technology

Contrast injector firm Medrad has introduced new extravasation detector technology for its Stellant CT injection system.

Medrad XDS uses radiofrequency (RF) wave technology and a physical property called permittivity to detect the start of an extravasation under a patient's skin and signal the Stellant to stop injections until a clinician can examine the patient. The product has been cleared by the U.S. Food and Drug Administration.

Six installations currently are operating at four clinical sites. The Warrendale, PA, company plans to begin full-scale XDS production in the fourth quarter.

Medrad demonstrated the product publicly for the first time this week at the 2007 American Healthcare Radiology Administrators (AHRA) annual meeting in Orlando.

By AuntMinnie.com staff writers
July 11, 2007

Related Reading

Medrad lands large Canadian order, July 10, 2007

Medrad grows revenues, workforce, March 20, 2007

Road to RSNA, Medrad, November 1, 2006

Consorta launches group buy promotions, October 31, 2006

Road to RSNA, Medrad, October 26, 2006

Copyright © 2007 AuntMinnie.com

Page 1 of 654
Next Page